ORIGINAL RESEARCH article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1566063
Impact of Secondary Hematologic Malignancies on Prognosis of Hodgkin’s Lymphoma Survivors
Provisionally accepted
- Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The purpose of this study is to report the differences in the prognosis of Hodgkin’s lymphoma (HL) survivors with or without secondary hematologic malignancies (SHM).Methods: This study included patients diagnosed with HL in the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching was used to balance the baseline differences between SHM and non-SHM patient groups, while survival analysis was used to compare the overall survival and long-term prognosis differences between the two groups.Results: A total of 36497 patients, along with 231 matched pairs, were included in the study, with a median follow-up time of eight years. The pre-matching multivariate Cox regression results showed that the non-SHM group had a 69% higher risk of all-cause mortality compared to the SHM group. The pre-matching Landmark method revealed no difference in survival between the two groups at < 30 months; at ≥ 30 months, the mortality risk in the SHM group was higher than that in the non-SHM group (HR = 5.188, 95% CI: 3.510, 7.667, P < 0.05). After matching, the Landmark method showed that at < 50 months, the mortality risk of the SHM group was lower than that of the non-SHM group (HR = 0.629, 95% CI: 0.434, 0.935, P<0.05). At ≥ 50 months, the mortality risk of the SHM group was higher than that of the non-SHM group (HR = 3.759, 95% CI: 2.667, 5.300, P < 0.05).Conclusion: The presence of SHM significantly increases the long-term mortality risk in Hodgkin’s lymphoma survivors.
Keywords: HL survivors, SHM, prognostic differences, Landmark curve, survival analysis
Received: 24 Jan 2025; Accepted: 15 Apr 2025.
Copyright: © 2025 Lin, Liu, Huang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fangheng Lin, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.